Rigel Pharmaceuticals | RIGL - Trade Creditors


Rigel Pharmaceuticals reported $3.85M in Trade Creditors for its fiscal quarter ending in September of 2025.





Trade Creditors Change Date
Agenus USD 71.08M 11.9M Mar/2026
Amgen USD 2.86B 16.65B Jun/2026
Anika Therapeutics USD 6.24M 103K Jun/2026
Arrowhead Research USD 27.78M 2.97M Jun/2026
AstraZeneca USD 22.89B 388M Jun/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Bristol-Myers Squibb USD 4.16B 76M Jun/2026
Celldex Therapeutics USD 10.36M 9.18M Mar/2026
Daiichi Sankyo JPY 539.05B 57.81B Jun/2026
Eli Lilly USD 6.11B 1.08B Jun/2026
Halozyme Therapeutics USD 14.1M 6.8M Mar/2026
Heron Therapeutics USD 8.97M 24K Mar/2026
Intrexon USD 4.85M 3.12M Jun/2024
Ionis Pharmaceuticals USD 47.7M 21.67M Jun/2026
Karyopharm Therapeutics USD 4.28M 276K Mar/2026
Ligand Pharmaceuticals USD 37.11M 33.87M Mar/2026
MacroGenics USD 4.29M 500K Mar/2026
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Pfizer USD 4.58B 75M Jun/2026
Regeneron Pharmaceuticals USD 1.16B 132.2M Jun/2026
Rigel Pharmaceuticals USD 3.85M 3.44M Sep/2025
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Ultragenyx Pharmaceutical USD 39M 3M Jun/2026
Veracyte USD 8.02M 1.12M Jun/2026